Skyhawk Therapeutics announced today a strategic collaboration with Merck KGaA, Darmstadt, Germany to discover and develop RNA-targeted small molecule therapies. The collaboration leverages Skyhawk's proprietary SkyAI and SkyStar platforms to identify novel therapies across multiple therapeutic areas.
PRESS RELEASE
Skyhawk Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany
Skyhawk and Merck KGaA enter a multi-target collaboration to discover and develop RNA-targeted small molecule therapies across multiple therapeutic areas.